Status:
COMPLETED
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Generalized Anxiety Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The primary purpose of this study is to evaluate the efficacy of (SEROQUEL SR™ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety symptoms in patients with ge...
Eligibility Criteria
Inclusion
- Male or female aged 18 to 65 years;
- A diagnosis of generalized anxiety disorder;
- Absence of current episode of major depression.
Exclusion
- The presence or history of schizophrenia and other psychotic disorders;
- Hypertension;
- A current diagnosis of cancer, unless in remission for at least 5 years
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2007
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT00322595
Start Date
May 1 2006
End Date
May 1 2007
Last Update
December 22 2008
Active Locations (86)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
City Bell, Buenos Aires, Argentina
2
Research Site
Godoy Cruz, Mendoza Province, Argentina
3
Research Site
Mendoza, Mendoza Province, Argentina
4
Research Site
Rosario, Santa Fe Province, Argentina